PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Nandrolone Decanoate (300 mg per ml)
Pharmacological Class: Synthetic Anabolic-Androgenic Steroid ($19\text{-nortestosterone}$ derivative / Progestational Anabolic)
Bioniche Pharma Nandrolone Decanoate 300 mg is a long-acting injectable anabolic steroid belonging to the $19\text{-nortestosterone}$ family. Formulated with a long decanoate ester for sustained systemic release, Bioniche Pharma Nandrolone Decanoate provides substantial tissue-building capacity, appetite stimulation, increased bone mineral density, and enhanced erythropoiesis with low intrinsic androgenicity.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
Bioniche Pharma Nandrolone Decanoate binds selectively to nuclear androgen receptors, promoting significant cellular nitrogen retention, collagen synthesis, and systemic muscle tissue accretion. Unlike testosterone, Bioniche Pharma Nandrolone Decanoate is reduced by $5\alpha$-reductase into dihydronandrolone (DHN), a significantly less potent androgen, yielding a favorable anabolic-to-androgenic therapeutic ratio. It exhibits moderate affinity for progesterone receptors and converts to estrogen at a low rate relative to native testosterone.
INDICATIONS & CLINICAL USE
- Adjunctive management of refractoriness or severe chronic anemias requiring red blood cell stimulation using Bioniche Pharma formulations.
- Therapeutic support in osteoporotic bone loss to enhance bone mineral density and collagen matrix synthesis under Bioniche Pharma treatment protocols.
- Palliative care for advanced, disseminated estrogen receptor-positive breast carcinoma in postmenopausal females.
- Therapeutic recovery in chronic wasting conditions, catabolic states, and tissue-depleting diseases with Bioniche Pharma anabolic support.
CONTRAINDICATIONS
- Contraindicated in pediatric patients and children.
- Confirmed or suspected carcinoma of the prostate gland or male breast cancer.
- Female patients, except those undergoing palliative treatment with Bioniche Pharma products for disseminated breast cancer.
- Active renal insufficiency, nephritis, or the nephrotic phase of nephritis.
- Cardiac failure, fluid retention, severe peripheral edema, or unmanaged hypocalcemia.
- Active liver disease with impaired bilirubin excretion, hepatic carcinoma, or primary testicular neoplasms.
- Pregnancy and lactation due to fetal masculinization and endocrine disruption risks.
- Known hypersensitivity to Bioniche Pharma Nandrolone Decanoate, carrier oils, or excipients in Bioniche Pharma injectables.
SPECIAL PRECAUTIONS & VIRILIZATION WARNINGS
- Virilization in Females: Signs during Bioniche Pharma therapy include acne vulgaris, facial/body hirsutism, increased libido, and hoarseness (dysphonia). Vocal hoarseness may be the initial manifestation of structural vocal cord changes, which can become long-lasting or irreversible if Bioniche Pharma therapy is not promptly halted.
- Pediatric & Prepubescent Effects: In prepubescent males, Bioniche Pharma therapy may induce increased frequency of erections and phallic enlargement; in females, early pubic hair development and clitoral hypertrophy may occur.
- Progestational & Endocrine Surveillance: Due to progestational activity, Bioniche Pharma Nandrolone Decanoate therapy can induce pituitary gonadotropin suppression and serum prolactin shifts; regular endocrine panel monitoring is recommended.
ADVERSE REACTIONS
- Endocrine & Reproductive: Suppression of endogenous pituitary-testicular axis, temporary oligospermia, gynecomastia, or fluid retention during Bioniche Pharma treatment.
- Hepatic & Cardiovascular: Alterations in liver function parameters, cholestasis, serum lipid shifts (reduction of HDL and elevation of LDL cholesterol), and secondary hypertension from sodium and fluid retention associated with Bioniche Pharma administration.
- Dermatological: Sebaceous gland stimulation, acne, and oily skin induced by Bioniche Pharma anabolic agents.
DOSAGE & ADMINISTRATION
Bioniche Pharma Nandrolone Decanoate must be administered via deep intramuscular injection. Regimens are determined and monitored under direct medical oversight:
- Adult Dosage: The standard therapeutic dose of Bioniche Pharma Nandrolone Decanoate ranges between 300 mg and 600 mg administered weekly, tailored to clinical objectives, diagnostic lab profiles, and patient tolerance.
STORAGE & HANDLING
Store Bioniche Pharma injectable products in a cool, dry place away from direct light exposure and excess ambient heat. Do not refrigerate or freeze Bioniche Pharma products. Keep strictly out of reach and sight of children.